Possible drug resistance during lapatinib treatment

Lapatinib is an oral, small-molecule tyrosine kinase inhibitor mainly used to treat HER2-positive advanced or metastatic breast cancer. Although lapatinib has shown good anti-tumor effects in clinical practice, as treatment progresses, some patients may develop drug resistance, resulting in weakened or even ineffective treatment effects. The emergence of drug resistance is one of the important challenges currently facing the field of targeted therapy and requires great attention.

The mechanism of lapatinib resistance is relatively complex, mainly including activation of alternative signaling pathways by tumor cells, structural changes in HER2 receptors, and changes in the tumor microenvironment. Some tumor cells bypass the restrictions of HER2 inhibition and achieve continued proliferation and survival by activating PI3K/AKT, MAPK and other downstream signaling pathways. In addition, HER2 gene mutations or changes in the degree of amplification may also lead to a decrease in the binding ability of lapatinib, thereby reducing the inhibitory effect of the drug.

Changes in immune cells, stromal cells and cytokines in the tumor microenvironment may also promote the development of drug resistance. For example, growth factors and inflammatory mediators secreted by tumor-associated macrophages can support tumor cells to evade immune surveillance and enhance drug resistance. In addition, the heterogeneity of cancer cells makes some subpopulations of cells naturally resistant to lapatinib, and selective pressure during treatment leads to the expansion of drug-resistant cells.

In the face of lapatinib resistance, clinical strategies such as combination use, dose adjustment, or replacement of other targeted drugs are often adopted. For example, combining lapatinib with hormonal therapy, chemotherapy, or immunotherapy can help delay the development of drug resistance. The new generation of HER2 inhibitors, such as trastuzumab and pertuzumab, also provide more treatment options for drug-resistant patients. Regular monitoring of treatment response and molecular markers can help timely detect drug resistance and adjust treatment plans, improving patients' quality of life.

Reference materials:https://www.drugs.com/